These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 31354255)
1. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD. Park TS; Kang J; Lee JS; Oh YM; Lee SD; Lee SW Int J Chron Obstruct Pulmon Dis; 2019; 14():871-879. PubMed ID: 31354255 [TBL] [Abstract][Full Text] [Related]
2. The Dosing Strategy to Improve Adherence to Roflumilast in Treatment for Chronic Obstructive Lung Disease: A Systemic Review and Meta-Analysis. Lee J; Song JU Int J Chron Obstruct Pulmon Dis; 2024; 19():655-663. PubMed ID: 38476122 [TBL] [Abstract][Full Text] [Related]
3. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. Watz H; Bagul N; Rabe KF; Rennard S; Alagappan VK; Román J; Facius A; Calverley PM Int J Chron Obstruct Pulmon Dis; 2018; 13():813-822. PubMed ID: 29563781 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease. Kim KH; Kang HS; Kim JS; Yoon HK; Kim SK; Rhee CK Int J Chron Obstruct Pulmon Dis; 2017; 12():3449-3456. PubMed ID: 29270006 [TBL] [Abstract][Full Text] [Related]
5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [TBL] [Abstract][Full Text] [Related]
6. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease. Facius A; Marostica E; Gardiner P; Watz H; Lahu G Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235 [TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Rogliani P; Calzetta L; Cazzola M; Matera MG Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341 [TBL] [Abstract][Full Text] [Related]
9. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930 [TBL] [Abstract][Full Text] [Related]
11. Roflumilast (Daliresp) for COPD. Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965 [No Abstract] [Full Text] [Related]
12. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586 [TBL] [Abstract][Full Text] [Related]
13. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study. Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114 [TBL] [Abstract][Full Text] [Related]
14. Roflumilast for severe COPD? Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576 [TBL] [Abstract][Full Text] [Related]
15. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384 [TBL] [Abstract][Full Text] [Related]
17. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis. Luo J; Wang K; Liu D; Liang BM; Liu CT Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407 [TBL] [Abstract][Full Text] [Related]
18. Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients. Liu DY; Wang ZG; Gao Y; Zhang HM; Zhang YX; Wang XJ; Peng D Medicine (Baltimore); 2018 Feb; 97(7):e9864. PubMed ID: 29443750 [TBL] [Abstract][Full Text] [Related]